One-year preliminary results from IVAN study shows ranibizumab and bevacizumab of similar efficacy for the treatment of neovascular AMD

Source: Ophthalmology
Area: News
One-year (preliminary) outcomes of the IVAN trial comparing ranibizumab with bevacizumab intravitreal injections for the treatment of neovascular age-related macular degeneration (AMD) have been published.   The trial involved 610 adults aged over 50 years, with previously untreated neovascular AMD in the study eye and best corrected visual acuity >/= 25 letters on the Early Treatment Diabetic Retinopathy Study chart. Patients from 23 hospitals and academic institutions in the UK were identified for inclusion. The primary endpoint is at 2 years (follow-up is ongoing), but the (Read more...)

Full Story →